The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses
Abstract
The presence of replication-competent adenoviruses (RCAs) in batches of replication-defective adenovirus (Ad) vectors is a major problem for the application of these vectors in gene therapy. RCAs are generated by recombination between sequences in the Ad vector and homologous Ad sequences in the helper cells, resulting in the acquisition by the vector of early region 1. To prevent the formation of RCAs, we have developed helper cell lines, which we named PER, and matched Ad vectors that do not have sequence overlap. PER cells contain the Ad serotype 5 (Ad5) E1A- and E1B-encoding sequences (Ad5 nucleotides 459–3510) under the control of the human phosphoglycerate kinase (PGK) promoter. We demonstrate that PER cells synthesize high levels of the Ad5 E1A and E1B proteins. The yields from PER cells of E1-deleted Ads are similar to those obtained from earlier helper cells, such as 911 and 293 cells. Propagation of matched Ad vectors, which lack Ad5 nucleotides 459–3510, in one of the PER clones, PER.C6, does not result in the generation of RCAs, in contrast to propagation in 293 cells. We conclude that the combination of PER.C6 cells and nonoverlapping El-deleted adenoviral vectors eliminates the problem of RCA generation by homologous recombination, and allows cost-effective production of safe, clinical-grade batches of recombinant Ad vectors. The authors describe a new helper cell line and matched, nonhomologous adenoviral vectors. The absence of homologous sequences prevents the formation of replication-competent adenoviruses as a result of homologous recombination between the vector and the adenovirus sequences in the helper cells. With these new cells, the yields of E1-deleted adenoviral vectors are similar to the yields obtained with the conventional 293 and 911 cell lines. In none of nine batches of adenoviral vectors produced in these new cells could replication-dependent adenovirus be detected. The authors conclude that this new cell–vector combination allows cost-effective production of safe, clinical-grade batches of recombinant adenovirus vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
Self-citationCharacteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793 · cited 1×
“The chetype (Graham et al, 1977) More recentiy, we have de-authors conclude that this new cell-vector combination al-scribed an altemative Ad helper cell line, human cell line lows cost-effective production of safe, clinical-grade batches (Fallaux et al, 1996) of recombinant adenovirus vectors.”
[1] Production of single-stranded plasmid DNA
Vieira, J., & Messing, J. (1987) · Methods in Enzymology · doi:10.1016/0076-6879(87)53044-0 · Cited by 2,597
Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.
Debbas, M., & White, E. (1993) · Genes & Development · doi:10.1101/gad.7.4.546 · Cited by 871
Jones, N., & Shenk, T. (1979) · Cell · doi:10.1016/0092-8674(79)90275-7 · Cited by 760
Bett, A. J., Haddara, W., Prevec, L., & Graham, F. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8802 · Cited by 744
Rao, L., Debbas, M., Sabbatini, P., Hockenbery, D., Korsmeyer, S., & White, E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7742 · Cited by 660
Fallaux, F. J., Kranenburg, O., Cramer, S. J., Houweling, A., van Ormondt, H., Hoeben, R. C., & van der Eb, A. J. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.2-215 · Cited by 512
Self-citationBiology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy
Gao, G. P., Yang, Y., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.12.8934-8943.1996 · Cited by 370
Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins
White, E., Cipriani, R., Sabbatini, P., & Denton, A. (1991) · Journal of Virology · doi:10.1128/jvi.65.6.2968-2978.1991 · Cited by 243
Cited by
Shaw, G., Morse, S., Ararat, M., & Graham, F. L. (2002) · The FASEB Journal · doi:10.1096/fj.01-0995fje · Cited by 797
Adenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669
Update on adenovirus and its vectors
Russell, W. C. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-11-2573 · Cited by 596
Vogels, R., Zuijdgeest, D., van Rijnsoever, R., Hartkoorn, E., Damen, I., de Béthune, M.-P., Kostense, S., Penders, G., Helmus, N., Koudstaal, W., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8263-8271.2003 · Cited by 467
Self-citationExpression systems for therapeutic glycoprotein production
Durocher, Y., & Butler, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.008 · Cited by 386
Brooks, A. R., Harkins, R. N., Wang, P., Qian, H. S., Liu, P., & Rubanyi, G. M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.516 · Cited by 362
Adenovirus vectors for gene delivery
Benihoud, K., Yeh, P., & Perricaudet, M. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00007-5 · Cited by 350
Gene therapy: the first decade
Mountain, A. (2000) · Trends in Biotechnology · doi:10.1016/s0167-7799(99)01416-x · Cited by 334
Holkers, M., Maggio, I., Liu, J., Janssen, J. M., Miselli, F., Mussolino, C., Recchia, A., Cathomen, T., & Gonçalves, M. A. F. V. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1446 · Cited by 312
Viral gene therapy strategies: from basic science to clinical application
Young, L. S., Searle, P. F., Onion, D., & Mautner, V. (2006) · The Journal of Pathology · doi:10.1002/path.1896 · Cited by 313
Gutless adenovirus: last-generation adenovirus for gene therapy
Alba, R., Bosch, A., & Chillon, M. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302612 · Cited by 303
New Insights on Adenovirus as Vaccine Vectors
Lasaro, M. O., & Ertl, H. C. (2009) · Molecular Therapy · doi:10.1038/mt.2009.130 · Cited by 263
A simple method for the rapid generation of recombinant adenovirus vectors
Anderson, R., Haskell, R., Xia, H., Roessler, B., & Davidson, B. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301197 · Cited by 258
Recent advances in mammalian protein production
Bandaranayake, A. D., & Almo, S. C. (2014) · FEBS Letters · doi:10.1016/j.febslet.2013.11.035 · Cited by 222
“C6 (Crucell) line was originally generated from human retinoblast cells immortalized by transfection with an E1 minigene for the cost-effective production of safe, clinical-grade recombinant adenovirus vectors [34].”
Methodvon der Thüsen, J. H., van Vlijmen, B. J. M., Hoeben, R. C., Kockx, M. M., Havekes, L. M., van Berkel, T. J. C., & Biessen, E. A. L. (2002) · Circulation · doi:10.1161/01.cir.0000015502.97828.93 · Cited by 203
Self-citationHuman cells: new platform for recombinant therapeutic protein production
Swiech, K., Picanço-Castro, V., & Covas, D. T. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.04.023 · Cited by 178
High-level expression of recombinant IgG in the human cell line per.c6
Jones, D., Kroos, N., Anema, R., Van Montfort, B., Vooys, A., Kraats, S. V. D., Helm, E. V. D., Smits, S., Schouten, J., Brouwer, K., et al. (2003) · Biotechnology Progress · doi:10.1021/bp025574h · Cited by 158
Self-citationAdenoviral vector DNA for accurate genome editing with engineered nucleases
Holkers, M., Maggio, I., Henriques, S. F. D., Janssen, J. M., Cathomen, T., & Gonçalves, M. A. F. V. (2014) · Nature Methods · doi:10.1038/nmeth.3075 · Cited by 138
Garuti, R., Jones, C., Li, W.-P., Michaely, P., Herz, J., Gerard, R. D., Cohen, J. C., & Hobbs, H. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509394200 · Cited by 91
Casademunt, E., Martinelle, K., Jernberg, M., Winge, S., Tiemeyer, M., Biesert, L., Knaub, S., Walter, O., & Schröder, C. (2012) · European Journal of Haematology · doi:10.1111/j.1600-0609.2012.01804.x · Cited by 88
“Of note, these cells were established by adenoviral transformation of human embryonic retina (45) and can be considered to be of neuronal origin.”
BackgroundSchiedner, G., Hertel, S., Bialek, C., Kewes, H., Waschütza, G., & Volpers, C. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-13 · Cited by 50
Metadata
- Authors
- Fallaux, F. J., Bout, A., van der Velde, I., van den Wollenberg, D. J. M., Hehir, K. M., Keegan, J., Auger, C., Cramer, S. J., van Ormondt, H., van der Eb, A. J., Valerio, D., & Hoeben, R. C.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1998-09
- Volume
- 9
- Issue
- 13
- Pages
- 1909-1917
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1973905531
- Cited by
- 479
- References
- 35
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.